Lupus & antiphospholipid syndrome
Immune-mediated thrombotic thrombocytopenic purpura with systemic lupus erythematosus: clinical features and outcome
Authors' conclusion
Patients with iTTP are prone to develop autoimmune features, and patients with SLE-iTTP have distinct clinical features and outcome.
Study context
- Population
- Patients with iTTP recruited in a registryiTTP registry
- Participants
- 1,409 patients
- Exposure
- iTTP with coexistent SLE vs age-sex matched idiopathic iTTP without SLE
- SLE-iTTPn = 79
- Outcome
- Clinical presentation and outcome
Methodological detailsage-sex matched
- Age-sex matched
Main finding
As reported in the abstract
- SLE-iTTP had more severe renal involvement and more prevalent cardiac involvement; CNS involvement less common than in idiopathic iTTP
- SLE-iTTP received more immunosuppressive agents
- No difference in response categories during the acute phase
- SLE-iTTP had superior ADAMTS13 relapse-free survival than idiopathic iTTP during follow-up
- Matched cohort
Observational data: associations, not effects.
Further findings
- Development of clinical SLE in idiopathic iTTP during follow-up
- 0 · events
Detectable ANAs without other clinical features of SLE
- Patients with detectable ANAs without other SLE features
- 437 (31%)
- Of these, diagnosed with SLE following iTTP diagnosis
- 33 (8%)
- Time to SLE diagnosis, months (IQR 7-65)
- 27
- Of these, developed another systemic autoimmune disease
- 32 (7%)
Original publication
Immune-mediated thrombotic thrombocytopenic purpura with systemic lupus erythematosus: clinical features and outcome. Lupus Sci Med. Published 28 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →